Search

Your search keyword '"Cartechini E"' showing total 132 results

Search Constraints

Start Over You searched for: Author "Cartechini E" Remove constraint Author: "Cartechini E"
132 results on '"Cartechini E"'

Search Results

1. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

2. Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study

3. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

4. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

5. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

6. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

7. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

8. Disability accrual in primary and secondary progressive multiple sclerosis

9. Comparative effectiveness in multiple sclerosis: A methodological comparison

10. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

11. Real-world experience with ocrelizumab in primary Progressive multiple sclerosis: Insights from the MSOCR-P cohort, a MSBase Registry sub-study

12. Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS

13. Early non-disabling relapses are associated with a higher risk of disability accumulation in people with relapsing-remitting multiple sclerosis

14. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

15. Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia

16. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration

17. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.

18. Confirmed disability progression as a marker of permanent disability in multiple sclerosis.

19. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

20. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

21. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

22. Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

23. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

24. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression (vol 208, 106180, 2021)

25. Long-term outcomes in patients presenting with optic neuritis: analyses of the MSBase registry

26. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.

27. Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis.

28. Variability of the Response to Immunotherapy among Sub-groups of Patients with Multiple Sclerosis.

29. Association of latitude and exposure to ultraviolet B radiation with severity of multiple sclerosis.

30. Disability accrual in primary-progressive & secondaryprogressive multiple sclerosis.

31. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

32. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

33. Pregnancy in a modern day multiple sclerosis cohort: predictors of postpartum relapse and disability progression

34. Pregnancy in a modern day multiple sclerosis cohort: predictors of relapse during pregnancy

35. Identification of Therapeutic Lag in Multiple Sclerosis

36. of Therapeutic Lag in Relapsing Multiple Sclerosis

37. Predicting long-term sustained disability progression in multiple sclerosis.

38. Introducing machine learning for full MS patient trajectories improves predictions for disability score progression.

39. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

40. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

41. Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia

43. Therapeutic lag in relapsing multiple sclerosis

44. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS

45. Predicting long-term sustained disability progression in multiple sclerosis

46. Modifiers of the effectiveness of MS immunotherapies

47. Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression

50. Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry

Catalog

Books, media, physical & digital resources